Compare Cassava Sciences Inc (FLNA) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs ProShares UltraPro QQQ ETF — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while ProShares UltraPro QQQ ETF trades at $70.28. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TQQQ | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $87.22 |
52-Week Low | $1.09 | $37.89 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
TQQQ is trading at $71.65, down 4.49% on the day amid a bearish technical outlook with moving averages signaling caution. The leveraged ETF faces scrutiny over its daily compounding costs and volatility amplification risks. Recent news highlights concerns about leveraged ETFs potentially increasing market instability while acknowledging their potential for significant returns during bull markets.
The outlook remains clouded by structural risks inherent to daily reset leverage, with potential for amplified losses during market downturns. While long-term performance has been strong during tech rallies, the 81% drawdown in 2022 versus the Nasdaq's 33% decline underscores the asymmetric risk profile. Current bearish technical signals suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
